We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+2.42%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$141M
AUM Growth
+$26.9M
Cap. Flow
+$26.9M
Cap. Flow %
19.02%
Top 10 Hldgs %
81.88%
Holding
105
New
20
Increased
10
Reduced
43
Closed
26

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$35.6M
2
SERA icon
Sera Prognostics
SERA
+$6.17M
3
IRON icon
Disc Medicine
IRON
+$555K
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$535K
5
ARDX icon
Ardelyx
ARDX
+$529K

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$584K
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$554K
3
CGON icon
CG Oncology
CGON
+$552K
4
BLTE
Belite Bio
BLTE
+$551K
5
APLS
Apellis Pharmaceuticals
APLS
+$549K

Sector Composition

Rank Sector Weight
1 Healthcare 24.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGOV icon
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$104B
$70.5M 49.86%
700,000
– –
XBI icon
2
State Street SPDR S&P Biotech ETF
XBI
$11.8B
$36.4M 25.75%
+284,900
New +$35.6M
SERA icon
3
Sera Prognostics
SERA
$85.6M
$4.87M 3.44%
+2,396,685
New +$6.17M
DFTX
4
Definium Therapeutics
DFTX
$5.99B
$658K 0.47%
34,800
-41
-0.1% -$696
TYRA icon
5
Tyra Biosciences
TYRA
$1.57B
$613K 0.43%
16,000
-5,853
-27% -$189K
ASND icon
6
Ascendis Pharma A/S
ASND
$16.5B
$572K 0.4%
2,500
-79
-3% -$17.7K
PHVS icon
7
Pharvaris
PHVS
$2.61B
$565K 0.4%
20,000
-511
-2% -$13.6K
CYTK icon
8
Cytokinetics
CYTK
$11.1B
$547K 0.39%
8,300
-13
-0.2% -$826
RPRX icon
9
Royalty Pharma
RPRX
$27.6B
$528K 0.37%
11,000
-2,826
-20% -$124K
KYMR icon
10
Kymera Therapeutics
KYMR
$10.4B
$525K 0.37%
6,300
-48
-0.8% -$3.8K
HALO icon
11
Halozyme
HALO
$12.3B
$519K 0.37%
8,026
– –
EXEL icon
12
Exelixis
EXEL
$14.1B
$512K 0.36%
11,948
– –
IRON icon
13
Disc Medicine
IRON
$3.18B
$512K 0.36%
+8,000
New +$555K
IONS icon
14
Ionis Pharmaceuticals
IONS
$10.5B
$511K 0.36%
6,800
– –
AGIO icon
15
Agios Pharmaceuticals
AGIO
$2.05B
$507K 0.36%
+15,000
New +$425K
NBIX icon
16
Neurocrine Biosciences
NBIX
$16.1B
$507K 0.36%
3,848
+114
+3% +$15.1K
INCY icon
17
Incyte
INCY
$26.2B
$499K 0.35%
5,300
-50
-0.9% -$4.99K
TARS icon
18
Tarsus Pharmaceuticals
TARS
$3.11B
$491K 0.35%
7,000
+481
+7% +$33.6K
VKTX icon
19
Viking Therapeutics
VKTX
$4.05B
$488K 0.35%
15,000
+286
+2% +$9.19K
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$32.3B
$485K 0.34%
1,465
+147
+11% +$50K
PRAX icon
21
Praxis Precision Medicines
PRAX
$10.6B
$483K 0.34%
1,500
-482
-24% -$149K
AXSM icon
22
Axsome Therapeutics
AXSM
$10.9B
$481K 0.34%
+2,845
New +$491K
NAMS icon
23
NewAmsterdam Pharma
NAMS
$3.29B
$480K 0.34%
15,000
+80
+0.5% +$2.61K
ARDX icon
24
Ardelyx
ARDX
$1B
$479K 0.34%
+80,000
New +$529K
IMVT icon
25
Immunovant
IMVT
$9.09B
$477K 0.34%
19,200
-1,105
-5% -$28.6K
1
2 3 4 5

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
AIMA
Ables Iannone Moore & Associates Savannah, Georgia $188M AUM 26.75% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q1 2026 Portfolio in Review

As of Q1 2026, PSP Research held 105 positions worth $141M, up 24% from $114M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

PSP Research deployed $26.9M of net new capital in Q1 2026, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 39% a quarter earlier.

On the sell side, the largest reduction was Amylyx Pharmaceuticals, an estimated $470K trimmed.

  • PSP Research's largest Q1 2026 buy was State Street SPDR S&P Biotech ETF: 284,900 shares worth $36.4M.
  • PSP Research added most to Alnylam Pharmaceuticals in Q1 2026, an estimated $50K increase.
  • PSP Research's biggest Q1 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $470K.
  • PSP Research fully exited Travere Therapeutics in Q1 2026, selling an estimated $584K.
  • PSP Research's ten largest holdings make up 82% of its $141M portfolio in Q1 2026.
  • PSP Research opened 20 new positions and closed 26 in Q1 2026.
  • PSP Research's portfolio value rose 24% quarter-over-quarter to $141M.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.